116
Participants
Start Date
October 16, 2018
Primary Completion Date
January 31, 2022
Study Completion Date
April 25, 2022
Oxaliplatin-based chemotherapy
"The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
Alkylating-based chemotherapy
"The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
Institut Paoli Calmettes, Marseille
Hôpital François Mitterrand - CHU Dijon Bourgogne, Dijon
Hôpital Rangueil - CHU Toulouse, Toulouse
Hôpital Trousseau - CHU Tours, Tours
Hôpital Nord - CHU Saint Etienne, Saint-Priest-en-Jarez
Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez
CHU d'Angers, Angers
Hôpital Robert Debré - CHU Reims, Reims
Centre Oscar Lambret, Lille
Hôpital Claude Hurriet - CHRU Lille, Lille
Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand
Hôpital Edouard Herriot - Hospices Civils de Lyon, Lyon
Hôpital Privé Jean Mermoz, Lyon
CH Annecy Genevois, Pringy
Hôpital Saint Louis - APHP, Paris
Hôpital Cochin - APHP, Paris
Hôpital Sud - CHU Amiens, Amiens
Hôpital Beaujon - APHP, Clichy
Institut Gustave Roussy, Villejuif
Hospices Civils de Lyon
OTHER